Citation profile for Jakub Hlavka

Jakub Hlavka : Citation Profile

University of Southern California (1% share)
Masarykova Univerzita (99% share)

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

Papers

RESEARCH ACTIVITY:

   6 years (2016 - 2022). See details.
   Cites by year: 0
   Journals where Jakub Hlavka has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 0 (0 %)

MORE DETAILS IN:

EconPapers Author's homepage

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/phl25
   Updated: 2024-12-03    RAS profile: 2024-01-11
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Jakub Hlavka.

Is cited by:

Dubois, Pierre (1)

Magnac, Thierry (1)

LEVAGGI, ROSELLA (1)

Boes, Stefan (1)

Cites to:

Lakdawalla, Darius (7)

Goldman, Dana (3)

Sood, Neeraj (2)

Romer, Paul (2)

Philipson, Tomas (2)

Jones, Charles (2)

Chen, Alice (1)

Etro, Federico (1)

Towse, Adrian (1)

Main data

Where Jakub Hlavka has published?

Recent works citing Jakub Hlavka (2024 and 2023)

Year	Title of citing document
2024	Optimal intertemporal curative drug expenses: The case of hepatitis C in France. (2024). Magnac, Thierry ; Dubois, Pierre. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629624000067. Full description at Econpapers \|\| Download paper
2024	Competition, value-based prices and incentives to research personalised drugs. (2024). Levaggi, Rosella. In: Socio-Economic Planning Sciences. RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697. Full description at Econpapers \|\| Download paper

Works by Jakub Hlavka:

Year	Title	Type	Cited
2017	Portfolio Society: On the Capitalist Mode of Prediction In: Science and Public Policy. [Full Text][Citation analysis]	article	0
2016	A Change is in the Air Emerging Challenges for the Cloud Computing Industry In: Working Papers. [Full Text][Citation analysis]	paper	0
2020	The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis In: Applied Health Economics and Health Policy. [Full Text][Citation analysis]	article	1
2021	The economics of alternative payment models for pharmaceuticals In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	2
2022	Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers In: PharmacoEconomics. [Full Text][Citation analysis]	article	0